• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 4:22:46 PM ET
    $PDLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PDLI alert in real time by email
    SC 13G/A 1 tm216325d3_sc13ga.htm SC 13G/A

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.           1           ) *

     

    PDL BioPharma Inc
    (Name of Issuer)

     

    Common Shares
    (Title of Class of Securities)

     

    69329Y104
    (CUSIP Number)

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x  Rule 13d-1(b)

      ¨  Rule 13d-1(c)

      ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the ACT but shall be subject to all other provisions of the Act (however, see the Notes).

     

    SEC 1745 (3-98)

     

     

     

     
    Page 2 of 12

       
    CUSIP No. 69329Y104

     

    1. Names of Reporting Persons. Brandes Investment Partners, L.P.
      I.R.S. Identification Nos. of above persons (entities only).   33-0704072

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ¨  
      (b) ¨  
    3. SEC Use Only  
    4. Citizenship or Place of Organization Delaware

    Number of 5. Sole Voting Power  
    Shares Bene-      
    ficially owned 6. Shared Voting Power 2,550,396
    by Each      
    Reporting 7. Sole Dispositive Power  
    Person With:      
      8. Shared Dispositive Power

    7,046,701

         
     9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,046,701

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11. Percent of Class Represented by Amount in Row (9) 6.17 %

     

    12. Type of Reporting Person (See Instructions) IA, PN

     

     
    Page 3 of 12

     

    CUSIP No. 69329Y104

     

    1. Names of Reporting Persons. CO-GP, LLC.
      I.R.S. Identification Nos. of above persons (entities only).   73-1677697

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ¨  
      (b) ¨  
    3. SEC Use Only  
    4. Citizenship or Place of Organization California

    Number of 5. Sole Voting Power  
    Shares Bene-      
    ficially owned 6. Shared Voting Power 2,550,396

    by Each      
    Reporting 7. Sole Dispositive Power  
    Person With:      
      8. Shared Dispositive Power

    7,046,701

         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,046,701 shares are deemed to be beneficially owned by CO-GP, LLC as a control person of the investment adviser.  CO-GP, LLC disclaims any direct ownership of the shares reported in this Schedule 13G, except for an amount that is substantially less than one per cent of the number of shares reported herein.

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11. Percent of Class Represented by Amount in Row (9) 6.17 %

     

    12. Type of Reporting Person (See Instructions) CO, OO (Control Person)

     

     
    Page 4 of 12

     

    CUSIP No. 69329Y104

     

    1. Names of Reporting Persons. Brandes Worldwide Holdings, L.P.
      I.R.S. Identification Nos. of above persons (entities only).   33-0836630

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ¨  
      (b) ¨  
    3. SEC Use Only  
    4. Citizenship or Place of Organization Delaware

    Number of 5. Sole Voting Power  
    Shares Bene-      
    ficially owned 6. Shared Voting Power 2,550,396
    by Each      
    Reporting 7. Sole Dispositive Power  
    Person With:      
      8. Shared Dispositive Power

    7,046,701

         
     9. Aggregate Amount Beneficially Owned by Each Reporting Person

    7,046,701 shares are deemed to be beneficially owned by Brandes Worldwide Holdings, L.P., as a control person of the investment adviser. Brandes Worldwide Holdings, L.P. disclaims any direct ownership of the shares reported in this Schedule 13G.

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11. Percent of Class Represented by Amount in Row (9) 6.17 %

     

    12. Type of Reporting Person (See Instructions) PN, OO (Control Person)

     

     
    Page 5 of 12

     

    CUSIP No. 69329Y104

     

    1. Names of Reporting Persons. Glenn Carlson
      I.R.S. Identification Nos. of above persons (entities only).        

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ¨  
      (b) ¨  
    3. SEC Use Only  
    4. Citizenship or Place of Organization USA

    Number of 5. Sole Voting Power  
    Shares Bene-      
    ficially owned 6. Shared Voting Power 2,550,396
    by Each      
    Reporting 7. Sole Dispositive Power  
    Person With:      
      8. Shared Dispositive Power

    7,046,701

         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,046,701 shares are deemed to be beneficially owned by Glenn Carlson, a control person of the investment adviser.  Mr. Carlson disclaims any direct ownership of the shares reported in Schedule 13G, except for the amount that is substantially less than one per cent of the number of shares reported herein.

     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11. Percent of Class Represented by Amount in Row (9) 6.17 %

     

    12. Type of Reporting Person (See Instructions) IN, OO (Control Person)

     

     
    Page 6 of 12

     

    Item 1(a)Name of Issuer:

     

    PDL BioPharma, Inc.

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    932 Southwood Blvd.

    Incline Village, NV 89451

     

    Item 2(a)Name of Person Filing:

     

    (i)Brandes Investment Partners, L.P.

    (ii)CO-GP, LLC

    (iii)Brandes Worldwide Holdings, L.P.

    (iv)Glenn Carlson

     

    Item 2(b)Address of Principal Business office or, if None, Residence:

     

    (i)11988 El Camino Real, Suite 600, San Diego, CA 92130

    (ii)11988 El Camino Real, Suite 600, San Diego, CA 92130

    (iii)11988 El Camino Real, Suite 600, San Diego, CA 92130

    (iv)11988 El Camino Real, Suite 600, San Diego, CA 92130

     

    Item 2(c)Citizenship

     

    (i)Delaware

    (ii)California

    (iii)Delaware

    (iv)USA

     

    Item 2(d)Title of Class Securities:

     

    Common Shares

     

    Item 2(e)CUSIP Number:

     

    69329Y104

     

     
    Page 7 of 12

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d)¨ Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8).

    (e)¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).

    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(ii)(F).

    (g)¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

    (j)x Group, in accordance with § 240.13d-1(b)(1)(ii)(J).

     

    This statement is filed by Brandes Investment Partners, L.P., an investment adviser registered under the Investment Advisers Act of 1940, its control persons and its holding company. (See, also, Exhibit A.)

     

    Item 4.Ownership:

     

    (a)Amount Beneficially Owned:      7,046,701

     

    (b)Percent of Class:      6.17 %

     

    (c)Number of shares as to which the joint filers have:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 2,550,396

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 7,046,701

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following ¨. N/A

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person. N/A

     

     
    Page 8 of 12

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    N/A

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit A

     

    Item 9.Notice of Dissolution of Group.

     

    N/A

     

    Item 10.Certification:

     

    (a)The following certification shall be included if the statement is filed pursuant to § 240.13d-1(b):

     

     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 8, 2021

     

      BRANDES INVESTMENT PARTNERS, L.P.
         
      By: /s/ Ian Rose
        Ian Rose as Attorney-In-Fact for
        Glenn Carlson, General Partner
        Co-GP, LLC its General Partner

     

      CO-GP, LLC
         
      By: /s/ Ian Rose
        Ian Rose as Attorney-In-Fact for
        Glenn Carlson, General Partner

     

      BRANDES WORLDWIDE HOLDINGS, L.P.
         
      By: /s/ Ian Rose
        Ian Rose as Attorney-In-Fact for
        Glenn Carlson of Co-GP, LLC its General Partner

     

      By: /s/ Ian Rose
        Ian Rose as Attorney-In-Fact for
        Glenn Carlson, Control Person

     

     
    Page 9 of 12

     

    EXHIBIT A

     

    Identification and Classification of Members of the Group

     

    Pursuant to Rule 13d-1(b)(ii)(J) and Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, the members of the group making this joint filing are identified and classified as follows:

     

    Name Classification
       
    Brandes Investment Partners, L.P. (the “Investment Adviser”) Investment adviser registered under Investment Advisers Act of 1940
       
    Co-GP, LLC A control person of the Investment Adviser
       
    Brandes Worldwide Holdings, L.P. A control person of the Investment Adviser
       
    Glenn Carlson A control person of the Investment Adviser

     

     
    Page 10 of 12

     

    EXHIBIT B

     

    Joint Filing Agreement Pursuant to Rule 13d-1

     

    This agreement is made pursuant to Rule 13d-1(b)(ii)(J) and Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the “Act”) by and among the parties listed below, each referred to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereunder may be filed on each of their behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1.

     

    Dated: February 8, 2021

     

      BRANDES INVESTMENT PARTNERS, L.P.
         
      By: /s/Glenn Carlson
        Glenn Carlson, General Partner of
        Co-GP, LLC.

     

      Co-GP, LLC.
         
      By: /s/Glenn Carlson
        Glenn Carlson, General Partner

     

     
    Page 11 of 12

     

    EXHIBIT C

     

    Power of Attorney for Schedules 13D, 13G and Form 13F

     

    I, Glenn Carlson, as member of Co-GP of LLC., which is a General Partner of Brandes Worldwide Holdings, L.P., and which is also the limited partner of Brandes Investment Partners, L.P., hereby appoint Ian N. Rose as attorney-in-fact and agent, in all capacities, to execute, on my behalf and on behalf of Co-GP LLC., Brandes Investment Partners, L.P., and Brandes Worldwide Holdings, L.P., to file with the appropriate issuers, exchanges and regulatory authorities, any and all Schedules 13D, 13G and Form 13F and documents relating thereto required to be filed under the Securities and Exchange Act of 1934, including exhibits, attachments and amendments thereto and request for confidential treatment of information contained therein in connection with my being a “control person” (as contemplated for purposes of Schedule 13D, 13G and Form 13F) of Brandes Investment Partners, L.P., its subsidiaries and affiliates. I hereby grant to said attorneys-in-fact full authority to do every act necessary to be done in order to effectuate the same as fully, to all intents and purposes, as I could if personally present, thereby ratifying all that said attorneys-in-fact and agents may lawfully do or cause to be done by virtue hereof.

     

    I hereby execute this Power of Attorney as of this 8th day of February 2021.

     

      /s/Glenn Carlson
      Glenn Carlson

     

     
    Page 12 of 12

     

    EXHIBIT D

     

    Disclaimer of Beneficial Ownership

     

    Co-GP, LLC, Brandes Worldwide Holdings, L.P., Glenn Carlson, and Jeff Busby disclaim beneficial interest as to the shares referenced above, except for an amount equal to substantially less than one percent of the shares reported on this Schedule 13D. None of these entities or individuals holds the above-referenced shares for its/his own account except on a de minimis basis.

     

      /s/Glenn Carlson
      Glenn Carlson

     

      /s/Jeff Busby
      Jeff Busby

     

     

     

    Get the next $PDLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PDLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PDLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

      2/12/21 3:20:51 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

      2/11/21 4:22:46 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PDLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting

      Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

      4/16/25 8:00:00 AM ET
      $AVID
      $FOR
      $HSON
      $IGT
      Computer Software: Prepackaged Software
      Technology
      Real Estate
      Finance
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PDLI
    Leadership Updates

    Live Leadership Updates

    See more

    $PDLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PDLI
    SEC Filings

    See more
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors

      SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. “I’m delighted to welcome Natasha to Alpine Immune Sciences’ Board at this important moment in our company’s history, as we build on our strategic partnership with AbbVie and leverage Alpine’s financial strength to further advance our development pipeline,” said Mitchell H. Gold, M.D., Executive

      12/11/20 8:00:00 AM ET
      $XOMA
      $PDLI
      $ALPN
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SEC Form 4: L.P. Capital Point Silver bought $383,475 worth of Common Stock (187,061 units at $2.05)

      4 - PDL BIOPHARMA, INC. (0000882104) (Issuer)

      2/3/21 5:57:54 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC TO-I/A filed

      SC TO-I/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

      2/19/21 5:13:05 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed

      EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

      2/4/21 12:15:29 AM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed

      EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

      2/4/21 12:15:31 AM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care